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Katalin A. Wilkinson,*,†,‡,1 Naomi F. Walker,*,x,1 Graeme Meintjes,*,†,x Armin Deffur,*
Mark P. Nicol,*,{,‖ Keira H. Skolimowska,*,x Kerryn Matthews,* Rebecca Tadokera,*
Ronnett Seldon,* Gary Maartens,† Molebogeng X. Rangaka,* Gurdyal S. Besra,# and
Robert J. Wilkinson*,†,‡,x
Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) frequently complicates combined antiretroviral ther-
apy and antituberculosis therapy in HIV-1–coinfected tuberculosis patients. The immunopathological mechanisms underlying TB-IRIS
are incompletely defined, and improved understanding is required to derive new treatments and to reduce associated morbidity and
mortality. We performed longitudinal and cross-sectional analyses of human PBMCs from paradoxical TB-IRIS patients and non-IRIS
controls (HIV-TB–coinfected patients commencing antiretroviral therapy who did not develop TB-IRIS). Freshly isolated PBMC
stimulated with heat-killed Mycobacterium tuberculosis H37Rv (hkH37Rv) were used for IFN-g ELISPOT and RNA extraction. Stored
RNAwas used for microarray and RT-PCR, whereas corresponding stored culture supernatants were used for ELISA. Stored PBMC
were used for perforin and granzyme B ELISPOTand flow cytometry. There were significantly increased IFN-g responses to hkH37Rv
in TB-IRIS, compared with non-IRIS PBMC (p = 0.035). Microarray analysis of hkH37Rv-stimulated PBMC indicated that perforin 1
was the most significantly upregulated gene, with granzyme B among the top five (log2 fold difference 3.587 and 2.828, respectively), in
TB-IRIS. Downstream experiments using RT-PCR, ELISA, and ELISPOT confirmed the increased expression and secretion of perforin
and granzyme B. Moreover, granzyme B secretion reduced in PBMC from TB-IRIS patients during corticosteroid treatment. Invariant
NKT cell (CD3+Va24+) proportions were higher in TB-IRIS patients (p = 0.004) and were a source of perforin. Our data implicate the
granule exocytosis pathway in TB-IRIS pathophysiology. Further understanding of the immunopathogenesis of this condition will
facilitate development of specific diagnostic and improved therapeutic options. The Journal of Immunology, 2015, 194: 1748–1754.
H
uman immunodeficiency virus-1 is recognized as the
strongest predisposing factor to tuberculosis (TB), and
TB is the commonest cause of death in HIV-1–infected
persons in Africa (1, 2). However, otherwise beneficial dual
therapy for HIV-1 and TB is frequently complicated by the oc-
currence of the TB-associated immune reconstitution inflamma-
tory syndrome (TB-IRIS), an early complication of combination
antiretroviral therapy (ART).
Two forms of TB-IRIS are recognized: paradoxical, which
occurs in patients established on antituberculosis therapy before
ART, but who develop recurrent or new TB symptoms and clinical
features after ART initiation; and unmasking TB-IRIS in patients
not receiving treatment for TB when ART is started, but who
present with active TB within 3 mo of starting ART (3). Para-
doxical TB-IRIS affects ∼15.9% of all HIV-1–infected patients
commencing ART while on TB treatment, and up to 54% in some
populations, causing considerable morbidity and mortality (4, 5).
Immunosuppressive corticosteroid therapy improves symptoms
and reduces hospital admissions, but is not without adverse events,
and is potentially detrimental in cases of drug-resistant TB (6–8).
Specific diagnostic tools and treatments for TB-IRIS are lacking,
and understanding the pathogenesis of this condition is important
to assist in the development of more specific therapies.
Risk factors for TB-IRIS, such as low CD4 count and dissem-
inated TB disease at presentation, suggest that a pathological
immune reaction to mycobacterial Ags during immune recovery is
responsible. We previously described highly dynamic Ag-specific
CD4 T cell IFN-g responses in the first weeks after ART initiation
in both TB-IRIS and control patients in response to early secretory
antigenic target-6, 38-kDa cell wall–associated Ag, and a-crys-
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tallins 1 and 2 (9). However, such PBMC Th1 expansions to
recombinant protein Ags of Mycobacterium tuberculosis were
common to both TB-IRIS patients and controls. We have subse-
quently shown a role for hypercytokinaemia, of predominantly
myeloid or dual myeloid/lymphoid origin in TB-IRIS as well as
matrix metalloproteinase dysregulation (10, 11). Moreover, the
beneficial effects of prednisone in TB-IRIS appear to be associ-
ated with suppression of proinflammatory cytokine responses of
innate immune origin (8, 12), suggesting that innate immune
responses may have a role in TB-IRIS pathophysiology.
In the current study, we compared the immune responses in
TB-IRIS patients with non-IRIS controls after restimulation with
heat-killed (hk) whole M. tuberculosis bacillus (using the H37Rv
laboratory strain), which contains a wide range of both protein
and nonprotein Ags. We found that restimulation with hkH37Rv
resulted in an increased IFN-g release by TB-IRIS PBMC, rais-
ing the possibility that a component of the T cell response is di-
rected toward nonprotein Ags and may be responsible for the
differential response. Unbiased analysis of hkH37Rv-stimulated
PBMC by microarray indicated increased abundance of tran-
scripts for granzyme B and perforin in TB-IRIS patients. Our
downstream RT-PCR, ELISA, and ELISPOT analyses confirmed
increased expression as well as secretion, implicating the in-
volvement of the granule exocytosis pathway in TB-IRIS patho-
physiology. A subset of PBMC expressing both CD3 and the
Va24 chain of the TCR, indicative of invariant NKT (iNKT) cells,
was increased in TB-IRIS patients and contributed to perforin
production. Our data support the hypothesis that the granule
exocytosis pathway plays a role in TB-IRIS pathophysiology, and
further study of this pathway may elucidate novel therapeutic
targets in TB-IRIS.
Materials and Methods
Participants
The University of Cape Town Faculty of Health Sciences Human Research
Ethics Committee (HREC references 337/2004, 173/2005) approved the
study. Participants provided written informed consent. Blood samples were
collected continuously and prospectively between March 2005 and De-
cember 2007 at Ubuntu Clinic, Site B Khayelitsha and G.F. Jooste Hospital.
Previous cross-sectional and longitudinal analyses of patients from this
cohort, including a randomized controlled trial of prednisone versus placebo
in TB-IRIS patients, have been reported (7, 9, 10). Active TB was diag-
nosed on the basis of smear or culture positivity, or in cases of smear-
negative TB, according to international guidelines (6, 10, 13). Patients
were started on first-line antituberculosis therapy according to national
guidelines. All patients were ART naive at enrollment. First-line ART at
the time of the study was most often stavudine, lamivudine, and efavirenz.
The diagnosis of TB-IRIS was made according to a consensus case defi-
nition that has been independently validated (3, 14, 15). Patients were
followed up at regular intervals for at least 2 mo post-ART initiation, and
those who did not develop TB-IRIS were designated non-IRIS controls.
The current analyses included 62 patients with TB-IRIS (38 female, 24
male, median age 31 y, median baseline CD4 count 57, median number of
days to development of IRIS symptoms was 14) and 34 non-IRIS patients
(25 female, 9 male, median age 35 y, median baseline CD4 count 50)
(Supplemental Table I). Among the 62 TB-IRIS patients, active TB was
diagnosed on the basis of smear or culture positivity in 51 (82.5%), or
according to international guidelines in cases of smear-negative TB (n = 11,
17.5%). Of the non-IRIS controls, 18 patients had microbiological confir-
mation of TB. No significant differences were found between IRIS and non-
IRIS patients regarding gender, baseline CD4 T cell counts, or age.
Sample collection and processing
Venous blood collected in sodium heparin vacutainers (BD Pharmingen)
was processed within 4 h of collection. PBMC were isolated by density-
gradient centrifugation over Ficoll. Freshly isolated PBMC were stimulated
with hkH37Rv and used for RNA extraction (as described below), as well as
measurement of IFN-g release by ELISPOT analysis, whereas remaining
PBMC were cryopreserved in temperature-monitored liquid nitrogen tanks.
ELISPOT analysis
IFN-g ELISPOT was performed using fresh PBMC, as previously de-
scribed (16, 17). Perforin and granzyme B ELISPOTs were performed
using stored PBMC (following overnight resting) and the human granzyme
B and human perforin ELISPOT kits (Mabtech AB), following the man-
ufacturer’s recommendations. Briefly, to detect human granzyme B,
polyvinylidene difluoride ELISPOT plates were prewet with 50 ml 70%
ethanol for 2 min, followed by washing five times with sterile water at 200
ml/well. A total of 15 mg/ml coating Ab (GB10) was added in sterile PBS
at 100 ml/well. After overnight incubation at 4˚C, the plate was washed five
times with PBS, and wells were blocked using RPMI 1640/10% FCS for
30 min at room temperature. Following the removal of the blocking me-
dium, cells were added at 250,000 per well in 100 ml RPMI 1640/10%
FCS, together with hkH37Rv at multiplicity of infection (MOI) = 1:1,
H37Rv to PBMC, or left unstimulated. The plate was incubated overnight
in the CO2 incubator at 37˚C. The following morning, the cells were re-
moved and the wells were washed five times with PBS. A total of 1 mg/ml
detection Ab (GB11-biotin) was added in PBS containing 0.5% FCS at 100
ml/well for 2 h at room temperature. The wells were washed, and diluted
streptavidin–alkaline phosphatase (1:1000) in PBS–0.5% FCS was added
at 100 ml/well for 1 h at room temperature. Following a final wash, the
wells were developed using the ready-to-use substrate solution 5-bromo-4-
chloro-3-indolyl phosphate/NBT-plus, and color development was stopped
using extensive washing with tap water. To detect human perforin-
secreting cells, mAb Pf-80/164-precoated ELISPOT plates were used,
which were washed four times with sterile PBS, followed by blocking with
RPMI 1640/10% FCS for 30 min at room temperature. Cells were added at
250,000 per well in 100 ml RPMI 1640/10% FCS, together with hkH37Rv
at MOI = 1:1, H37Rv to PBMC, or left unstimulated as controls. The plate
was incubated in the CO2 incubator at 37˚C for 24 h. Following removal of
the cells, wells were washed five times with PBS, and the detection Ab (Pf-
344-biotin), diluted to 1 mg/ml in PBS–0.5% FCS, was added at 100 ml/
well for 2 h at room temperature. Wells were washed again, and strepta-
vidin–alkaline phosphatase, diluted 1:1000 in PBS–0.5% FCS, was added
at 100 ml/well for 1 h at room temperature. The wells were developed, as
above. Results were counted using an AID ELISPOT reader (AID GmbH
Germany, equipped with software version 5), and are reported as spot-
forming cells per million/106 PBMC with the unstimulated backgrounds
subtracted. A positive response was defined as .30 spot-forming cells per
million/106 PBMC. All results were checked for data consistency and plausi-
bility as per Minimal Information About T Cell Assays reporting requirements.
RNA and protein secretion assays
For transcriptomic analysis, fresh PBMCwere plated at a density of 13 106
cells/ml, 5 ml per well in 6-well plates, rested overnight at 37˚C, and then
stimulated with hkH37Rv (MOI = 1:1, H37Rv to PBMC) for 6 or 24 h, or
remained unstimulated. Cells were then lysed in cold RLN buffer (RNeasy
mini kit for total RNA isolation; Qiagen, Valencia, CA). RNA was
extracted using RNeasy Mini Kit Spin protocol as per the manufacturer’s
instructions (Qiagen), and used for quantitative RT-PCR, as described (8,
10). Fold induction over unstimulated cultures was calculated by the DD
cycle threshold method, and fold values log transformed to normalize. For
RT-PCR, b-actin was used to normalize values. For protein secretion
assays, cell culture supernatants were harvested at 24-h stimulation and
stored at280˚C until measurement of granzyme A and B by ELISA (Bender
MedSystems, Vienna, Austria), following the manufacturer’s protocol.
Microarray analysis
Samples consisted of RNA extracted from PBMC stimulated with
hkH37Rv, as described above, from seven TB-IRIS and seven control
samples, matched by clinical data (age, sex, duration of antituberculosis
therapy, and CD4 count), with one condition per patient (stimulated samples
only) at a single time point (6 h). Samples were hybridized to an Affymetrix
U133+ GeneChip, following standard procedures. Raw data files were
processed using the PLIER algorithm, which incorporates background
correction (ArrayAssist Lite; Stratagene, Cedar Creek, TX). Normalized
data were log2 transformed; IRIS and non-IRIS samples were paired on the
basis of clinical data and analyzed using Significance Analysis of Micro-
arrays 3.0 (18), using the following parameters: seed for random number
generator = 1234567, log2 scale = TRUE, median centering of array data =
TRUE, analysis type = “Two class paired,” number of permutations = 200,
and false discovery rate = 0.000001. In compliance with Minimum In-
formation About a Microarray Experiment, the data were deposited in the
National Center for Biotechnology Information’s Gene Expression Om-
nibus repository, with accession number GSE48237 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE48237).
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Flow cytometry
Flow cytometric analysis was performed using cryopreserved PBMC.
Viability was ascertained by trypan blue exclusion. Cells were washed, and
then stained on ice for 20 min with the following fluorescent Abs in vari-
ous combinations: CD3 (PerCP-Cy5.5 or allophycocyanin) or FITC, anti–
TCR-ab-1-FITC, and anti–TCR-gd-1-PE (all BD Oncomark); Va24
TCR-FITC and Vb11 TCR-PE (Immunotech); CD56-PE, CD107a-PE,
CD94-allophycocyanin, CD158b-PE, and CD16–PerCP-Cy5.5 (all from
BD Pharmingen); and CD158a–PerCP-Cy5.5 (eBiosciences). After washing,
stained cells were fixed in PBS/2% FCS/1.6% paraformaldehyde and ac-
quired on a FACSCalibur flow cytometer (BD Biosciences). For intracel-
lular staining, cells were first surface stained, followed by washing and
incubation for 30 min on ice with Fix/Perm buffer (eBioscience). After
washing in permeabilization buffer, cells were incubated for 30 min on ice
with perforin-PE (Perforin reagent set; BD Pharmingen 556437) or IFN-g
allophycocyanin. The cells were washed again, fixed in PBS/2% FCS/1.6%
paraformaldehyde, and acquired. Data were analyzed using Flowjo soft-
ware (Tree Star, Ashland, OR).
Statistical analysis
Statistical analysis was performed using GraphPad Prism. The normality of
data was assessed by the D’Agostino and Pearson omnibus normality test.
Medians are quoted with the interquartile range (IQR). Paired parametric
data were analyzed by Student paired t test, and nonparametric paired data
were analyzed by Wilcoxon matched-pairs test. Unpaired parametric var-
iables were assessed by Student unpaired t test, and nonparametric vari-
ables were assessed by Mann–Whitney U test. Significance was inferred
from a p value ,0.05.
Results
Differential IFN-g response to hkH37Rv in TB-IRIS patients
We investigated the IFN-g response to hkH37Rv in PBMC ob-
tained from a prospective cohort of 38 HIV-TB–coinfected patients
at baseline and 2-wk interval post-ART initiation. The clinical
characteristics of the patients are shown in Supplemental Table I
and have been previously described (9). Of the 38 TB patients, 11
developed TB-IRIS at a median of 2 wk (14 d, IQR 11–18 d) of
ART. At this time, the median number of IFN-g spot-forming cells
per 106 PBMC was 329 (IQR 107–905) in TB-IRIS patients,
compared with 16.5 (IQR 0–336) in non-IRIS controls (p = 0.035;
Fig. 1). There was no significant difference between IFN-g responses
at baseline, or weeks 4 and 8 post-ART initiation. These results
indicate differentially increased IFN-g release by TB-IRIS PBMC at
the time of IRIS, which contrasts with our previous observations in
response to recombinant protein Ags (9). Because hkH37Rv con-
tains a wide range of protein and nonprotein Ags, these results raise
the possibility that a component of the T cell response in TB-IRIS
patients may be directed toward nonprotein Ags and may be re-
sponsible for the differential response.
Increased transcript abundance for granzyme B and perforin in
TB-IRIS PBMC
To explore differences between stimulated PBMC from patients
with TB-IRIS as compared with non-IRIS patients that would
account for the differentially increased IFN-g release by TB-IRIS
PBMC in response to hkH37Rv shown above, we investigated
differential transcript abundance by microarray analysis of RNA
from PBMC stimulated for 6 h with hkH37Rv. Seven TB-IRIS
patients were compared with seven non-IRIS controls. RNA from
unstimulated PBMC was not included as we wished to compare
hkH37Rv stimulation-specific TB-IRIS gene expression with
similarly stimulated non-IRIS controls. Clinical characteristics of
the patients are shown in Supplemental Table I. The most sig-
nificantly upregulated gene at 2 wk post-ART initiation (the me-
dian time of TB-IRIS onset) was perforin 1 identified by two
individual probes for PRF1 gene (median log2 fold change = 3.587
and 3.092, respectively). Granzyme B was among the top five
most significantly upregulated genes in TB-IRIS (median log2 fold
change = 2.828), with d = 0.96 and false discovery rate of 0%
(Fig. 2, and data deposited GSE48237). Thus, unbiased analysis
by microarray suggested the involvement of the granule exocy-
tosis pathway in TB-IRIS at the time of IRIS, and we proceeded to
downstream validate these findings for perforin and granzyme B.
Secondary validation of microarray analysis by RT-PCR,
ELISA, and ELISPOT
To biologically and technically validate the microarray findings,
quantitative RT-PCR analysis was performed in a second set of
RNA samples from a larger number of 22 TB-IRIS and 22 non-IRIS
control patients. The clinical characteristics of these patients are
shown in Supplemental Table I and were previously reported (10).
Freshly isolated PBMC at 2 wk post-ART initiation were cultured
in the presence or absence of hkH37Rv for 6 or 24 h. Cell culture
supernatants were collected at 24 h, whereas RNA was extracted
at both time points and assayed, as described (10). Granzyme B
transcript abundance was increased in TB-IRIS compared with
non-IRIS controls after both 6 and 24 h (p , 0.0001 and p =
0.002, respectively; Fig. 3). Perforin transcript was also significantly
more abundant after 24 h (p = 0.008). Granzyme A was included
as an internal control and showed no difference in abundance
between the groups at any time point.
Next we evaluated granzyme A and B protein secretion in the
PBMC culture supernatants collected at 24 h poststimulation with
hkH37Rv in a subset of 20 TB-IRIS and 20 non-IRIS control
patients, using ELISA. We found significantly increased granzyme
B concentrations in TB-IRIS patients (median, 1617 pg/ml; IQR,
826.5–5227) compared with non-IRIS controls (median, 332.5
pg/ml; IQR, 42.50–1486; p = 0.002; Fig. 4A) and compared with
unstimulated cultures. By contrast, granzyme Awas not increased
(Fig. 4B).
To confirm perforin secretion, we opted to employ the more
sensitive ELISPOT methodology based on Zuber et al. (19),
showing that the ELISPOT displayed greater detection sensitivity
than the ELISA when assessing perforin release. Because gran-
FIGURE 1. IFN-g responses to hkH37Rv in TB-IRIS compared with
non-IRIS control PBMC during the first 8 wk post-ART initiation. IFN-g
responses of PBMC measured by ELISPOT from 38 HIV-TB–coinfected
patients at baseline and for 8 wk post-ART initiation, after stimulation with
hkH37Rv. Eleven patients developed TB-IRIS at a median of 14 d. Sig-
nificantly increased numbers of IFN-g spot-forming cells (SFC) were
identified in TB-IRIS patients at TB-IRIS onset, compared with non-IRIS
control patients sampled at 2 wk of ART (p = 0.035). No differences in
IFN-g SFC were identified at other time points. Horizontal lines indicate
median values.
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zyme A was consistently shown not to be elevated in our internal
control experiments, we did not include it in the ELISPOT anal-
ysis, but we included measurement of granzyme B to further
strengthen our findings. Thus, ELISPOT assay for perforin and
granzyme B was performed in a smaller number of samples, based
on stored PBMC availability. A nonsignificant trend toward in-
creased numbers of PBMC-secreting granzyme B and perforin in
response to hkH37Rv in TB-IRIS was observed (Fig. 4C, 4D). The
median spot-forming cells per 106 PBMC for granzyme B from
TB-IRIS patients was 92 (IQR, 0–364) compared with 48 (IQR,
1.25–94) in non-IRIS patients. For perforin, the median from
TB-IRIS patients was 44 (IQR, 6.5–87) in TB-IRIS and 27 (IQR,
4.5–52) in non-IRIS patients.
The effect of in vivo prednisone therapy on granzyme B
secretion in vitro
Corticosteroid therapy is used as an immunosuppressive therapy
in the treatment of TB-IRIS. We evaluated granzyme B secretion
by ELISA in the 24-h supernatant of hkH37Rv-stimulated PBMC
cultures from a subset of 29 patients enrolled in a randomized
double-blind placebo-controlled trial of prednisone for treatment
of TB-IRIS (7, 8). The trial showed an overall reduction in dura-
tion of hospitalization and numbers of therapeutic procedures in
prednisone-treated patients, as well as hastened improvement in
TB-IRIS symptoms (7, 8), and such trends were evident in the
subset of patients included in this analysis. Thus, we observed that
in TB-IRIS patients receiving prednisone treatment for 2 wk,
granzyme B secretion was decreased in vitro (n = 16; median, 233
pg/ml; IQR, 66–2312 pg/ml) compared with pretreatment responses
(median, 1068; IQR, 6–6672; p = 0.03). This reduction was not
evident in PBMC from placebo-treated patients (n = 13; Fig. 5),
suggesting a correlation between our in vitro assessment of perforin
and granzyme B and improved clinical outcome (7, 8).
Elucidating the cellular source of perforin in TB-IRIS patients
Our findings suggested the differential induction of cytotoxic
pathways in TB-IRIS in response to hkH37Rv. We therefore in-
vestigated potential cytotoxic cells present in PBMC at 2 wk post-
ART initiation in a subgroup of patients using flow cytometry. As
both CD8 and CD4 T cells are able to upregulate mRNA expression
for granzyme B and perforin after stimulation with H37Rv (20), we
first evaluated differences between these cells in TB-IRIS com-
pared with non-IRIS controls. CD4 and CD8 T cells were present
in similar proportions in unstimulated PBMC in TB-IRIS and non-
IRIS controls (Supplemental Fig. 1A). In a subset of patients, we
established that both CD4 and CD8 cells contained perforin
FIGURE 2. Representation of significantly differentially expressed genes. Microarray analysis of RNA from seven matched pairs of IRIS and non-IRIS
patients, at 2 wk on ART, showed transcript for perforin and granzyme B genes to be among the four genes most significantly overrepresented in TB-IRIS
PBMC after stimulation with H37Rv. The transcripts for Zinc and ring finger 1 and Cbp/p300-interacting transactivator with Glu/Asp-rich C-terminal
domain 2 were also significantly raised. The genes significantly upregulated in TB-IRIS (with d = 0.96 and false discovery rate of 0.000001%) are rep-
resented on the volcano plot as labeled. The x-axis shows the log2-fold change, and the y-axis shows a measure of significance (2log10 [p value]).
FIGURE 3. Secondary validation of microarray analysis by RT-PCR. PBMC from 22 TB-IRIS and 22 non-IRIS control patients were isolated and
cultured in the presence or absence of hkH37Rv (MOI 1:1, PBMC:H37Rv) for 6 or 24 h. RNAwas extracted and assayed by RT-PCR. b-actin was used to
normalize values. Fold induction over unstimulated cultures was calculated by the DD cycle threshold method, and fold values log10 transformed to
normalize. Granzyme B was increased in TB-IRIS compared with controls after both 6 and 24 h (p, 0.0001 and p = 0.002, respectively). Perforin was also
significantly increased after 24-h stimulation (p = 0.008). Horizontal lines indicate median values.
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(Supplemental Fig. 1B), which decreased on stimulation with
hkH37Rv, implying Ag-specific degranulation (as shown in a
smaller subset of patients in Supplemental Table II). Next, we
quantified NK cell proportions, identified by the absence of CD3,
the presence of CD16, and a combination of activating (CD56) or
inhibitory (CD94, CD158) cell surface receptors. No difference in
NK cell proportions was observed in TB-IRIS, compared with
non-IRIS controls (Supplemental Table III). The g-d (gd) T cells
have been implicated in TB-IRIS pathophysiology, can recognize
nonprotein Ags, and express perforin and granzyme B (21, 22).
We observed a trend toward decreased proportions of gd TCR-
expressing cells in TB-IRIS compared with non-IRIS PBMC
(Supplemental Table III; p = 0.089), suggesting that this pop-
ulation is less likely to contribute to upregulation of the cytotoxic
pathways identified.
iNKT cells may express either CD4 and/or CD8 molecules, are
innate lymphocytes with cytotoxic activity, and are characterized
by reactivity to glycolipid Ags. We investigated proportions of
iNKT cells, as determined by the presence of Va24 TCR that, in
combination with Vb11, characterizes these cells in humans.
Significantly increased proportions of CD3+ Va24+ cells were
found in unstimulated PBMC at 2 wk post-ART initiation from
TB-IRIS patients: median, 0.17% (IQR, 0.09–0.22; n = 15),
compared with non-IRIS controls (median, 0.03%; IQR, 0.016–
0.106; n = 9; p = 0.004; Fig. 6A). Using the more stringent
combination of Va24+Vb11+ staining on CD3+ cells in a smaller
number of TB-IRIS patients (n = 11), the median CD3+Va24+
Vb11+ frequency was 0.18% (IQR, 0.09–0.4) compared with 0.04%
(IQR, 0.03–0.82; n = 9) in nine non-IRIS patients (p = 0.05;
Supplemental Fig. 1C). Moreover, intracellular staining in a subset
of these TB-IRIS patient samples identified these cells as a source
of perforin (Fig. 6B).
Discussion
Defining the pathophysiology of TB-IRIS may facilitate devel-
opment of diagnostic tests and specific treatments, which are
currently lacking. Although dysregulated immune restoration is
associated with dynamic CD4 Th1 expansions and contractions,
these relate poorly to symptoms (8, 9). In our previous longitudinal
analysis, we found no evidence for a difference between TB-IRIS
and non-IRIS patients in response to recombinant protein Ags and
purified protein derivative, suggesting that protein Ag-specific Th1
responses may not be the primary determinants of TB-IRIS. The
finding in our current study, that increased IFN-g responses occur
in response to hkH37Rv in TB-IRIS patients at TB-IRIS onset
compared with non-IRIS controls, raises the possibility that a com-
ponent of the T cell response directed toward nonprotein Ags may
be responsible for the differential response.
Our microarray analysis, demonstrating perforin 1 and gran-
zyme B to be the most significantly upregulated genes in PBMC
from TB-IRIS patients, compared with non-IRIS controls, and
further validation of these results with RT-PCR, ELISA, and
ELISPOT, highlights a role for the granule–exocytosis pathway in
TB-IRIS. Perforin is a cytolytic protein found in granules of
FIGURE 4. Granzyme B and perforin secretion are increased in TB-IRIS. (A and B) Granzyme B secretion measured by ELISA was significantly in-
creased in TB-IRIS patients, in contrast to granzyme A, in hkH37Rv-stimulated PBMC culture supernatants (20 TB-IRIS, 20 controls) compared with
unstimulated supernatants (p , 0.0001), and compared with stimulated PBMC culture supernatants from non-IRIS control patients (p = 0.002). (C and D)
Granzyme B and perforin measured by ELISPOT tended to be increased in TB-IRIS compared with controls (not statistically significant). Horizontal lines
indicate median values.
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innate lymphocytes (cytotoxic T lymphocytes and NK cells) and
neutrophils that have a key role in delivery of contents of cyto-
toxic granules to target cell cytoplasm. Granzyme B is a serine
protease, a key component of cytotoxic granules, and activates
apoptosis once in the cytoplasm of the target cell. Potential cell
types that are capable of recognizing nonprotein Ags have cyto-
toxic capacity and contain granule-associated perforin and gran-
zyme B, including NK cells, gd T cells, and NKT cells (21, 23,
24). Two recent studies have examined the potential contribution
of NK cells in TB-IRIS and suggested that elevated NK cell ac-
tivation and degranulation levels characterize the immunological
profile of TB-IRIS patients (25, 26). One previous study also
demonstrated an association between a subset of gd T cells and
TB-IRIS (22). However, we found reduced proportions of these
cells in TB-IRIS, suggesting that they cannot be responsible for
the increased perforin and granzyme B detected in TB-IRIS
patients. We demonstrate that both CD4 and CD8 cells were
a source of perforin in TB-IRIS patients and that increased pro-
portions of iNKT cells are present in PBMC of TB-IRIS patients
at the time of IRIS onset, compared with non-IRIS controls, in two
analyses (calculating CD3+Va24+ cells and CD3+Va24+Vb11+
cells), both considered to be stringent approaches for quantifying
iNKT cells (27). Although these results implicate iNKT cells as
a likely candidate, we are currently conducting a longitudinal
study addressing further the role of cytotoxic T cells in TB-IRIS
development.
We have previously demonstrated that TB-IRIS is associated
with hypercytokinaemia in blood and cerebrospinal fluid, of pre-
dominantly myeloid or dual myeloid/lymphoid in origin, which is
modulated during treatment of TB-IRIS with corticosteroids (10,
12, 28). These and other studies exploring murine models of
TB-IRIS have led to the recent proposal that ART-induced changes
in innate immune function contribute substantially to TB-IRIS
(11, 28, 29). Our observation that granzyme B gene upregulation
and protein secretion occur in PBMC from patients at the time of
TB-IRIS symptom onset, and that secretion is reduced in PBMC
from patients treated for TB-IRIS by prednisone, which improves
symptoms and reduces hospitalization, supports a role for cyto-
toxic mediators in the immunopathology of TB-IRIS. Further
characterization of this cytotoxic response, especially at the site of
infection, is desirable.
Our study has a number of limitations, including the limited
number of cells available for in-depth analysis of cytotoxic lym-
phocytes. Inclusion of samples based on availability of PBMC
means that some of the assays were performed in samples from
different patients, possibly resulting in the introduction of se-
lection bias. However, it is encouraging to find the same pattern of
mediators in different samples collected over time. Our study design
did not include the evaluation of nonprotein preparations such as
lipid fractions, and we acknowledge the fact that, whereas killed
mycobacteria will no longer secrete protein Ags, they still contain
antigenic proteins, some of which will give rise to an immune re-
sponse. Additionally, we did not assess the capacity of neutrophils to
produce cytotoxic mediators. Evaluating the role of the two addi-
tional genes that were upregulated in TB-IRIS (ZNRF1: Zinc and
ring finger 1 and CITED2: Cbp/p300-interacting transactivator with
Glu/Asp-rich C-terminal domain 2) was outside the scope of the
current study and should constitute the subject of further investi-
gation.
In conclusion, our data indicate differential cytotoxic activity
associated with TB-IRIS, with increased cytotoxic mediators com-
pared with non-IRIS patients. This supports further analysis of
cytotoxic pathways, not only in TB-IRIS pathophysiology, but also
in the pathogenesis of tuberculosis and inflammatory conditions in
general. Improved understanding of the mechanisms of pathology
in TB-IRIS is required to derive new treatments to reduce the
morbidity and mortality associated with this condition.
FIGURE 5. Effect of prednisone or placebo on granzyme B release
in vitro. Granzyme B secretion (pg/ml) from PBMCs, from TB-IRIS patients
enrolled in a randomized controlled trial of prednisone versus placebo,
measured by ELISA after stimulation with hkH37Rv, with unstimulated
culture results subtracted. Prednisone treatment for 2 wk significantly de-
creased granzyme B secretion from TB-IRIS PBMC compared with pre-
treatment values. This reduction was not evident in PBMC from placebo-
treated TB-IRIS patients.
FIGURE 6. Increased proportions of iNKT cells in TB-IRIS compared
with non-IRIS control patients. Flow cytometric analysis using cell surface
staining for CD3+Va24+ cells identified an increased proportion of CD3+
Va24+ cells in TB-IRIS compared with non-IRIS control patients (median,
0.17%; IQR, 0.09–0.22, versus 0.03%; IQR, 0.016–0.106) (A). Using in-
tracellular staining for perforin, CD3+Va24+ cells from TB-IRIS patients
were identified as a potential source of perforin (B). Horizontal bars in-
dicate median values. Gating strategy was based on selecting CD3+ cells
from a side scatter/CD3 scatter dot blot, followed by gating on Va24 and
either Vb11 or perforin-positive cells.
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